Results 61 to 70 of about 788,607 (367)
Journal of Intensive Care, 2018 BackgroundAlthough factor Xa inhibitors have become a popular choice for chronic oral anticoagulation, effective drug reversal remains difficult due to a lack of specific antidote.
J. Tao, E. Bukanova, S. Akhtar
semanticscholar +1 more source
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]
, 2017 Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core +1 more source
The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant [PDF]
, 2020 One of the most common mutations in the serine protease inhibitor Kazal type 1 (SPINK1) gene is the N34S variant which is strongly associated with chronic pancreatitis. Although it is assumed that N34S mutation constitutes a high-risk factor, the underlying pathologic mechanism is still unknown.
arxiv +1 more source
Molecules, 2023 Despite extensive research in the field of thrombotic diseases, the prevention of blood clots remains an important area of study. Therefore, the development of new anticoagulant drugs with better therapeutic profiles and fewer side effects to combat ...
Nadezhda P. Novichikhina +12 more
doaj +1 more source
Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile [PDF]
, 2016 Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation process. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors.
Afosa, Daniel K. +4 more
core +4 more sources
SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS
Атеротромбоз, 2016 Safety profiles of the novel oral anticoagulants (NOAC) (rivaroxaban, apixaban, edoxaban, dabigatran) are better than that of warfarin. However, the risk (including lifethreatening) of bleeding is no less than 2.3–3.1% per year.
O. O. Shakhmatova
doaj +1 more source
Thrombosis and Haemostasis, 2018 Oral factor Xa inhibitors are increasingly used for anticoagulation, but there is no approved reversal agent. Prothrombin complex concentrate (PCC) for the management of Xa-inhibitor–associated bleeding has been described in small case series and one ...
S. Schulman +10 more
semanticscholar +1 more source
Role of Cold Storage in Rooting of Stem Cuttings: A Review [PDF]
, 2023 Cold storage is a strategy mainly used for ornamental cuttings for the purpose of prolonging production duration that provide the cuttings with the best condition at the time of planting. The results have been obtained from cold storage of carnations and chrysanthemums confirmed the fact that the herbaceous cuttings could be stored for about two months
arxiv +1 more source
Management of anticoagulation in clinical practice [PDF]
, 2021 This thesis describes various aspects of the anticoagulation management of patients with atrial fibrillation and venous thromboembolism. In this thesis, we focus on the management of direct oral anticoagulants (DOACs).
Bavalia, R.
core
Lupus, 2019 Objective The objective of this study was to clarify the efficacy and safety of factor Xa inhibitors for antiphospholipid syndrome patients in real world utilization. Methods This is a retrospective cohort study comprised of all consecutive patients with
Takahiro Sato +11 more
semanticscholar +1 more source